Problem of Drug Interactions in the Treatment of Patients with COVID-19 and Comorbid Conditions
https://doi.org/10.37489/0235-2990-2021-66-7-8-45-49
Abstract
The article discusses the issues of drug interactions in the treatment of COVID-19 patients with concomitant cardiovascular diseases. It was revealed, that the most frequent comorbid background in patients with COVID-19 is cardiac pathology. Cardiac arrhythmias are observed in many cases, which can be aggravated by the proarrhythmogenic effect of drugs used to treat the novel coronavirus disease.
About the Authors
R. M. Aramisova
Kabardino-Balkarian State University named after H. M. Berbekov
Russian Federation
Russian Federation
Rina M. Aramisova — D. Sc. in medicine, Professor
Nalchik
Z. A. Kambachokova
Kabardino-Balkarian State University named after H. M. Berbekov
Russian Federation
Russian Federation
173 Chernyshevskogo st., Nalchik, Kabardino-Balkarian Republic, 360004
Zareta A. Kambachokova — D. Sc. in medicine
Z. A. Akhkubekova
Kabardino-Balkarian State University named after H. M. Berbekov
Russian Federation
Russian Federation
Zukhra A. Akhkubekova — postgraduate student of Hospital Therapy Department
Nalchik
L. L. Logvina
Kabardino-Balkarian State University named after H. M. Berbekov
Russian Federation
Russian Federation
Larisa L. Logvina — Ph. D. in medicine
Nalchik
M. M. Sarbasheva
Kabardino-Balkarian State University named after H. M. Berbekov
Russian Federation
Russian Federation
Marziyat M. Sarbasheva — Ph. D. in medicine
Nalchik
S. M. Chudopal
Kabardino-Balkarian State University named after H. M. Berbekov
Russian Federation
Russian Federation
Sergei M. Chudopal — Ph. D. in medicine
Nalchik
L. B. Tlapshokova
Kabardino-Balkarian State University named after H. M. Berbekov
Russian Federation
Russian Federation
Larisa B. Tlapshokova — D. Sc. in medicine, Professor
Nalchik
L. M. Taukenova
Kabardino-Balkarian State University named after H. M. Berbekov
Russian Federation
Russian Federation
Leyla M. Taukenova — Associate Professor of the Department of Neurology, Psychiatry, and Narcology
Nalchik
A. R. Tambiev
Kabardino-Balkarian State University named after H. M. Berbekov
Russian Federation
Russian Federation
Aslan R. Tambiev — Assistant of the Department of Neurology, Psychiatry, and Narcology
Nalchik
K. R. Pshukov
Kabardino-Balkarian State University named after H. M. Berbekov
Russian Federation
Russian Federation
Kazemir R. Pshukov — 2nd year student of General Medicine Department
Nalchik
References
1. Bazdyrev E.D. Koronavirusnaya infektsiya — aktual'naya problema XXI veka. Kompleksnye Problemy Serdechno-Sosudistykh Zabolevanij. 2020; 9 (2): 6–16. (in Russian)
2. Larina V. N., Golovko M. G., Larin V. G. Vliyanie koronavirusnoj infektsii (Covid-19) na serdechno-sosudistujyu sistemu. Vestnik RGMU. 2020; 2: 5–13. (in Russian)
3. Chazova I.E., Mironova O.Jyu. COVID-19 i serdechno-sosudistye zabolevaniya. Terapevticheskij Arkhiv. 2020; 9: 4–7. (in Russian)
4. Barbarash O.L., Karetnikova V.N., Kashtalap V.V. i dr. Novaya koronavirusnaya bolezn' (COVID-19) i serdechno-sosudistye zabolevaniya. Kompleksnye Problemy Serdechno-Sosudistykh Zabolevanij. 2020; 2: 17–28. (in Russian)
5. Danilova I.A. Zabolevaemost' i smertnost' ot COVID-19. Problema sopostavimosti dannykh. Demograficheskoe Obozrenie. 2020; 7: 6–26. (in Russian)
6. Shlyakhto E. V., Konradi A. O. Villeval'de S. V. Rukovodstvo po diagnostike i lechenijyu boleznej sistemy krovoobrashcheniya (BSK) v kontekste pandemii COVID-19. Rossijskij Kardiologicheskij Zhurnal. 2020; 25 (3): 129–148. (in Russian)
7. Aghagoli G., Gallo M. B., Soliman L. B., Selke F.W. Cardiac involvement in COVID-19 patients: Risk factors, predictors, and complications: A review. J Card Surg. 2020; 35 (6): 1302–1305. doi: 10.1111/jocs.14538. Epub 2020 Apr 19.
8. Richardson S., Hirsch J.S., Narasimhan M. et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. JAMA. 2020; 323: pp. 2052–2059.
9. Guan W., Liang W., Zhao Y. et al. Comorbidity and its impact on 1590 patients with COVID-19 in China: A nationwide analysis. Eur Respir J. March 14; 55 (5): 2000547. doi: 10.1183/13993003.00547-2020.
10. Wu Z., McGoogan J.M. Characteristics of and Important Lessons from the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020 Apr 7; 323 (13): 1239–1242. doi: 10.1001/jama.2020.2648.
11. Grinevich V. B., Gubonina I. V., Doshchitsin V. L. I dr. Osobennosti vedeniya komorbidnykh patsientov v period pandemii novoj koronavirusnoj infektsii (COVID-19). KardiovasKulyarnaya Terapiya i Profilaktika. 2020; 19 (4): 135–172. (in Russian)
12. Kozlov I.A., Tjyurin A.N. Serdechno-sosudistye oslozhneniya COVID-19. Vestnik Anesteziologii i Reanimatologii. 2020; 17 (4): 14–22. (in Russian)
13. Colon C.M., Barrios J.G., Chiles J.W., McElwee S.K., Russell D.W., Maddox W.R., Kay G.N. Atrial arrhythmias in COVID-19 patients. JACC Clin Electrophysiol. 2020 Sep; 6 (9): 1189–1190. doi: 10.1016/j.jacep.2020.05.015.
14. Itkonen M.K., Tornio A., Lapatto-Reiniluoto O., Neuvonen M., Neuvonen P., Niemi M., Backman J.T. Clopidogrel Increases Dasabuvir Exposure With or Without Ritonavir, and Ritonavir Inhibits the Bioactivation of Clopidogrel. Clin Pharmacol Ther. 2019; 105 (1): 219–228. doi: 10.1002/cpt.1099.
15. Ray W., Murray K., Hall K., Arbogast P., Stein M. Azithromycin and the risk of cardiovascular death. New Engl J Med. 2012; 366 (20): 1881–1890. doi: 10.1056/NEJMoa1003833.
16. Rosenberg E.S., Dufort E.M., Udo T. et al. Association of treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in New York state. JAMA. 2020; 323 (24): 2493–2502. doi: 10.1001/jama.2020.8630.
17. Simpson T., Salazar J., Vittinghoff E. et al. Association of QT prolonging medications with risk of autopsy causes of sudden death. JAMA Int Med. 2020; 180 (5): 698–706. doi: 10.1001/jamainternmed.2020.0148.
18. Fossa A., Wisialowski T., Duncan J., Deng S., Dunne M. Azithromycin/chloroquine combination does not increase cardiac instability despite an increase in monophasic action potential duration in the anesthetized guinea pig. Am J Trop Med Hyg. 2007; 77 (5): 929–938.
19. Gautret P., Lagier J., Parola P. et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020; 56 (1): 105949. doi: 10.1016/j.ijantimicag.2020.105949.
Review
For citations:
Aramisova R.M., Kambachokova Z.A., Akhkubekova Z.A., Logvina L.L., Sarbasheva M.M., Chudopal S.M., Tlapshokova L.B., Taukenova L.M., Tambiev A.R., Pshukov K.R. Problem of Drug Interactions in the Treatment of Patients with COVID-19 and Comorbid Conditions. Antibiot Khimioter = Antibiotics and Chemotherapy. 2021;66(7-8):45-49. (In Russ.) https://doi.org/10.37489/0235-2990-2021-66-7-8-45-49
Views:
867
Email this article 